홈 › 급성 골수성 백혈병 › 매사추세츠 › Boston
MA Boston의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 44개가 Boston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
피험자 모집 중2상
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Ivosidenib as Post-HSCT Maintenance for AML
피험자 모집 중2상
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
피험자 모집 중1상
- Dana-Farber Cancer Institute, Boston
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
피험자 모집 중3상
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Tufts Medical Center, Boston
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
피험자 모집 중1/2상
- Dana-Farber Cancer Center, Boston
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
피험자 모집 중3상
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
피험자 모집 중2상
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
피험자 모집 중1/2상
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
피험자 모집 중1상
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
피험자 모집 중1상
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
피험자 모집 중1상
- Dana-Farber Cancer Institute, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
피험자 모집 중1/2상
- Dana-Farber Cancer Institute, Boston
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
피험자 모집 중1상
- Dana-Farber Cancer Institute, Boston
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
피험자 모집 중3상
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
피험자 모집 중1상
- Beth Israel Deaconess Medical Center, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
피험자 모집 중1상건강한 지원자 환영
- Brigham and Women's Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
피험자 모집 중관찰 연구
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
피험자 모집 중1상
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
피험자 모집 중1상
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
피험자 모집 중1상
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
피험자 모집 중관찰 연구
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
피험자 모집 중1상
- Dana Farber Cancer Institute, Boston
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
피험자 모집 중1상
- Beth Israel Deaconess Medical Center, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
피험자 모집 중2/3상
- Dana-Farber Cancer Institute, Boston
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
피험자 모집 중2상
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
피험자 모집 중1상
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
Ziftomenib Maintenance Post Allo-HCT
피험자 모집 중1상
- Massachusetts General Hospital, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
피험자 모집 중2상
- Dana-Farber Cancer Institute, Boston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
피험자 모집 중1상
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
피험자 모집 중1상
- Massachusetts General Hospital, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
피험자 모집 중2상건강한 지원자 환영
- DFCI/BWH Brigham and Women's Hospital, Boston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
피험자 모집 중1상
- DFCI, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
피험자 모집 중1/2상
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Novel Digital Application for Patients With Acute Leukemia
피험자 모집 중
- Massachusetts General Hospital (MGH), Boston
IS-free Treg HaploHCT
피험자 모집 중1상
- Dana Farber Cancer Institute, Boston
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
피험자 모집 중건강한 지원자 환영
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
피험자 모집 중1상
- Dana Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
피험자 모집 중1상
- Massachusetts General Hospital, Boston
다른 도시의 급성 골수성 백혈병 시험
- Houston, TX연구 85개
- New York City, NY연구 51개
- Seattle, WA연구 41개
- Baldwin Park, CA연구 40개
- Columbus, OH연구 35개
- Philadelphia, PA연구 34개
- Durham, NC연구 33개
- Atlanta, GA연구 31개
- Tampa, FL연구 29개
- Chicago, IL연구 26개
- Portland, OR연구 25개
- Washington, DC연구 24개
Boston의 다른 연구
- 유방암연구 112개
- 비소세포폐암연구 90개
- 암 (전체)연구 85개
- 전이성 암연구 63개
- 대장직장암연구 63개
- 폐암연구 62개
- 난소암연구 61개
- 전립선암연구 59개
- 우울증연구 52개
- 자궁내막암연구 50개
- 심부전연구 44개
- 췌장암연구 43개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.